NHC Comments on Landmark FDA Guidance for Diversity in Clinical Trials
Putting Patients First Blog
SEPTEMBER 26, 2024
Further discussion on the unique aspects of rare disease drug development, the associated challenges, and when waivers may be warranted would greatly benefit all stakeholders, including sponsors, patient organizations, clinical researchers, and regulators. Clinical Pharmacology & Therapeutics , 97(3) , 263–273.
Let's personalize your content